Literature DB >> 12740868

Differential effects of amphetamine transport vs. dopamine reverse transport on particulate PKC activity in striatal synaptoneurosomes.

Cecilia T Giambalvo1.   

Abstract

Amphetamine has been shown to increase striatal particulate protein kinase C (PKC) activity [Giambalvo (1992b) Neuropharmacology 31:1211-1222]. The present study examined possible mechanisms involved. Specifically, the effects of calcium, endogenous DA, and DA receptors on the amphetamine-induced increase in PKC activity in striatal synaptoneurosomes were examined. Naïve rats and rats pretreated with N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinolone (EEDQ, i.p.), a nonselective irreversible receptor antagonist, or with alpha-methyl-p-tyrosine (AMPT, i.p.), a DA synthesis inhibitor, were sacrificed and striatal synaptoneurosomes were prepared. The tissue was incubated with amphetamine, with and without calcium, and PKC activity was then determined by the endogenous phosphorylation of endogenous substrate proteins, as described previously [Giambalvo (1988a) Biochem Pharmacol 37:4001-4007]. It was found that calcium enhanced the effect of amphetamine on PKC activity, even in rats pretreated with EEDQ. Intracellular calcium was required since pretreatment with 1,2-bis (2-aminophenoxy) ethane-N, N, N, N-tetracetic acid acetoxymethyl ester (BAPTA-AM) in vitro attenuated the amphetamine-induced increase in PKC activity, resulting in an inhibition of PKC activity instead. Likewise, endogenous DA was essential since pretreatment with AMPT resulted in a similar amphetamine-induced inhibition of PKC activity. Pretreatment with AMPT did not alter the inhibitory effect of the D2 DA agonist, LY 171555, on PKC activity. It did, however, abolish the calcium-dependent stimulatory effect of the D1 agonist SKF 38393 on PKC activity, rendering it inhibitory regardless of calcium. Considering that both BAPTA-AM and AMPT pretreatments, which diminished DA release without affecting uptake via different mechanisms, produced similar inhibitory effects on PKC activity by amphetamine, these results suggest that the inward transport of amphetamine had an inhibitory effect on PKC activity. In contrast, the outward transport of DA seemed to have a stimulatory effect on PKC activity since incubation with low sodium or with ouabain, conditions that promote DA reverse-transport, increased PKC activity. These results showed that PKC activity was altered differently during inward vs. outward transport. The amphetamine-induced increase in PKC activity was attenuated by pretreatment with DA uptake blockers (nomifensine, GBR 12935, and bupropion), even though these drugs by themselves also increased PKC activity. This effect was diminished by calcium and persisted in rats pretreated with EEDQ. Thus, calcium had a differential effect on the PKC activity induced by a transported substrate (amphetamine) vs. nontransported inhibitors (DA uptake blockers). Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740868     DOI: 10.1002/syn.10223

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

1.  Computational modeling of the N-terminus of the human dopamine transporter and its interaction with PIP2 -containing membranes.

Authors:  George Khelashvili; Milka Doktorova; Michelle A Sahai; Niklaus Johner; Lei Shi; Harel Weinstein
Journal:  Proteins       Date:  2015-03-25

2.  PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.

Authors:  Alexander G Zestos; Sarah R Mikelman; Robert T Kennedy; Margaret E Gnegy
Journal:  ACS Chem Neurosci       Date:  2016-03-28       Impact factor: 4.418

Review 3.  The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango.

Authors:  Harald H Sitte; Michael Freissmuth
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

Review 4.  Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action.

Authors:  Caline S Karam; Jonathan A Javitch
Journal:  Adv Pharmacol       Date:  2017-10-25

5.  Ruboxistaurin Reduces Cocaine-Stimulated Increases in Extracellular Dopamine by Modifying Dopamine-Autoreceptor Activity.

Authors:  Alexander G Zestos; Colleen Carpenter; Youngsoo Kim; Malcolm J Low; Robert T Kennedy; Margaret E Gnegy
Journal:  ACS Chem Neurosci       Date:  2018-11-08       Impact factor: 4.418

6.  Dopamine transporter phosphorylation site threonine 53 regulates substrate reuptake and amphetamine-stimulated efflux.

Authors:  James D Foster; Jae-Won Yang; Amy E Moritz; Sathyavathi Challasivakanaka; Margaret A Smith; Marion Holy; Kyle Wilebski; Harald H Sitte; Roxanne A Vaughan
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 7.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

8.  N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux.

Authors:  Habibeh Khoshbouei; Namita Sen; Bipasha Guptaroy; L 'Aurelle Johnson; David Lund; Margaret E Gnegy; Aurelio Galli; Jonathan A Javitch
Journal:  PLoS Biol       Date:  2004-03-16       Impact factor: 8.029

9.  Spontaneous inward opening of the dopamine transporter is triggered by PIP2-regulated dynamics of the N-terminus.

Authors:  George Khelashvili; Nathaniel Stanley; Michelle A Sahai; Jaime Medina; Michael V LeVine; Lei Shi; Gianni De Fabritiis; Harel Weinstein
Journal:  ACS Chem Neurosci       Date:  2015-08-17       Impact factor: 4.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.